Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CREATIC

Financiado

Central European Advanced Therapy and Immunotherapy Centre

Progress in biomedical science enables scientists to use a whole new toolbox to treat significant groups of diseases, such as inherited rare diseases or diverse rare cancers. Advanced therapy medicinal products (ATMPs) apply recen... ver más

31/08/2029

15M€

Presupuesto del proyecto: 15M€

Líder del proyecto

Masarykova univerzita No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 4 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-27

HORIZON-WIDERA-2022-ACCESS-01-01-two-stage: Teaming for Excellence Expected Outcome:Disparities in R&I performance are due to, among other reasons, the insufficien...

Innovación

Cerrada hace 3 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

4 Participantes

10.14M€ | Lider

Fraunhofer

1.67M€ | Participante

UCPH

1.53M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2020-119537RB-I00 INTEGRACION DE DATOS MULTI-OMICOS PARA LA INFERENCIA DE MODE... 242K€ Cerrado

CTGCT Centre of Excellence for the Technologies of Gene and Cell T... 14M€ Cerrado

SAF2017-90781-REDI FOMENTO DEL USO DE LAS TECNOLOGIAS OMICAS EN MEDICINA PERSON... 79K€ Cerrado

Cellphmed Accurate cell signatures for the advancement of personalized... 150K€ Cerrado

PRIME Prime editing to Repair Inherited Metabolic Errors: in vivo... 1M€ Cerrado

PDC2021-121243-I00 PLATAFORMA DELFOS: SISTEMA DE INFORMACION PARA LA GESTION DE... 102K€ Cerrado

Duración del proyecto: 76 meses Fecha Inicio: 2023-04-27
Fecha Fin: 2029-08-31

Líder del proyecto

Masarykova univerzita No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 15M€

Descripción del proyecto Progress in biomedical science enables scientists to use a whole new toolbox to treat significant groups of diseases, such as inherited rare diseases or diverse rare cancers. Advanced therapy medicinal products (ATMPs) apply recent advances in genomics, cell biology and/or gene editing to deliver truly personalized curative options. The project proposes to establish flagship ATMP-focused facility on the margin of academia and clinics: Central European Advanced Therapy and Immunotherapy Centre (CREATIC) at the Masaryk University (MU) in Brno, Czech Republic. MU will team up with the leading European research institutions: (1) Fraunhofer Institute for Cell Therapy and Immunology IZI, (2) Leipzig University, which together forms a significant cluster of research excellence in research, development and training in the fields of gene and cell therapies and (3) Copenhagen University with unique expertise in biomedical innovation law, intellectual property, biomedical ethics, privacy and regulatory framework, and health technology assessment. Combining STM and SSH disciplines the project will allow for (i) fundamental expansion of the scope of the R&I activities of all partners to build multidisciplinary excellence facilitating the delivery of ATMPs to patients who need them; (ii) establishment of the high level of decision-making autonomy for the CREATIC, which will allow significant organizational and management changes creating spirit and conditions for cutting-edge research and innovation in the Centre, and (iii) strengthen the smart specialization of the Czech Republic (RIS3 CZ 2021-2027) in the domain of Advanced medicine and drugs through the involvement of actors from the academic, public, private and societal sector. Our approach reflects research priorities and societal challenges outlined in the Pharmaceutical Strategy for Europe, which proposes ‘bedside’ manufacture of highly individualised medicines as a future trend in treating rare diseases with ATMPs.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores